Mantle Cell Lymphoma (MCL) Recruiting Phase 1 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02257242Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell LymphomaTreatment
NCT02914938A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTreatment
NCT02446236Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaTreatment
NCT03523975Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaTreatment
NCT03623373Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell LymphomaTreatment